Exicure Inc (XCUR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.89-10.34%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · XCUR
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement WILMINGTON, Del., September 16, 2026 – Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today ann…
Stated in a supplied disclosure. Management reported: “Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement WILMINGTON, Del., September 16, 2026 – Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that, on September 10, 2026, it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) granting the Company an extension through December 2, 2026 to regain compliance with Nasdaq Listing Rule 5550(b)(1).” “Under the terms of the extension, the Company must complete its compliance initiatives and publicly demonstrate compliance with the applicable stockholders’ equity requirement on or before December 2, 2026.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 3 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
About Exicure, Inc. Exicure, Inc. is a biotechnology company currently pursuing strategic initiatives designed to strengthen its financial position, maximize the value of its assets and establish a f…
Stated in a supplied disclosure. Management reported: “About Exicure, Inc. Exicure, Inc. is a biotechnology company currently pursuing strategic initiatives designed to strengthen its financial position, maximize the value of its assets and establish a foundation for future investment and business growth.” “Following its restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value.”
The delay was primarily due to additional time required following changes in the Company’s financial reporting personnel and related filing procedures.
Stated in a supplied disclosure. Management reported: “The delay was primarily due to additional time required following changes in the Company’s financial reporting personnel and related filing procedures.” “The Company filed its Quarterly Report on Form 10-Q for the three months ended March 31, 2026 with the Securities and Exchange Commission on May 29, 2026 and believes that it has regained compliance with Nasdaq Listing Rule 5250(c)(1).”
Focus on progressing lead programs in development for hematologic diseases and stem cell mobilization.
Appoint key executives to enhance management capabilities and support strategic initiatives.
Over the trailing year it converted 3.55x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
25 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.